Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as advanced or metastatic triple negative breast cancer in collaboration with Pfizer Inc. It has research and development collaboration agreement with National Canc...
